Media Release
Bosch Australia’s Manufacturing Solutions Division (BAMS), a leading supplier of factory automation for the medical device industry, announced today that digital diagnostics company, Ellume, would introduce BAMS technology to automate the high volume production of its COVID-19 diagnostic tests.
Brisbane based Ellume has developed a suite of COVID-19 tests for use by laboratories, doctors and consumers that gives results in less than 15 minutes. The Ellume technology was developed to address the unprecedented global demand for rapid, accurate diagnostics. The first batch of product has already been shipped to the United States and Ellume’s new manufacturing facility in Richlands, Brisbane, is rapidly scaling-up its production capacity.
With extensive experience in precision assembly and production automation, BAMS will work closely with Ellume’s Engineering Team to build and install state-of-the-art automated assembly lines to increase production capacity. The assembly lines will include end of line functional testing to ensure reliable product quality.
“We are delighted to bring the BAMS automation expertise to support Australian med-tech manufacturing for a global market – a real positive for local manufacturing, and a positive for the testing and medical diagnosis of COVID-19”, said Gavin Smith, President of Bosch Australia.
Ellume CEO and founder Dr Sean Parsons said, “We’ve spent the last decade perfecting our technology, and now, in the midst of the COVID-19 pandemic, the role of rapid, accurate diagnostics has never been more important. Ellume is pleased to be working with Bosch to bring their world-leading automation know-how to our manufacturing process. This will allow Ellume to manufacture best-in-class diagnostics that can be relied on in a health crisis.”
With deep experience in factory automation solutions, and a growing portfolio of med-tech clients, BAMS has the ability to create robust and resilient manufacturing processes for Ellume.
Image credit: www.bosch.com.au
